US · Healthcare · Medical Devices
EPS came in at -0.31 against a street estimate of -0.42 — a beat of 26.2%.
Analysts rate Vivos Therapeutics Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $2.12.
| Fund | Stake |
|---|---|
| Armistice Capital, LLC | 12.02% |
| Vanguard Capital Management, LLC | 2.94% |
| Geode Capital Management, LLC | 1.03% |
| Commonwealth Equity Services, LLC | 0.46% |
| IHT Wealth Management, LLC | 0.44% |
| National Asset Management Inc | 0.41% |
| Centurion Wealth Management LLC | 0.38% |
| Vanguard Fiduciary Trust Co | 0.33% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vivos Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.